Abstract
The term rifamycins indicates a large group of related compounds sharing as a common structural feature, a naphthohydroquinone chromophore spanned by a an aliphatic ansa chain. Originally, a mixture of five compounds, designated rifamycins A–E, was isolated from the fermentation broth of Nocardia mediterranei (Sensi et al. 1959 a, b). It was subsequently found that one of the compounds, rifamycin B, was produced almost exclusively when sodium diethylbarbiturate was present in the fermentation medium (Margalith and Pagani 1961). Chemical modification of this compound, particularly in the 3 position, yielded additional compounds with more extensive antimicrobial activity. The best known of these is the derivative 3-(4-methylpiperazinoiminomethyl) rifamycin SV, or more simply, rifampicin.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adamson R (1971) Antitumor activity of two antiviral drugs — rifampicin and tilorone. Lancet I: 398
Adamson RH, Sieber SM, Whang-Peng J, Wood HB (1976) Experimental studies with the antitumor agent maytansine. Proc Am Assoc Cancer Res 17: 42
Asai M, Mizuta E, Izawa M, Haibara K, Kishi T (1979) Isolation, chemical characterization and structure of ansamitocin, a new antitumor ansamycin antibiotic. Tetrahedron 35: 1079–1085
Baltimore D (1970) RNA-dependent DNA polymerase in virions of RNA tumor viruses. Nature 226: 1209–1211
Barlati S, Vigier P (1972) Effect of two rifamycin derivatives on the Rous sarcoma virus transformation system. J Gen Virol 17: 221–225
Barlati S, Vigier P (1972b) Selective inhibition of Rous sarcoma virus production in transformed chick fibroblasts by two rifamycin derivatives. FEBS Letters 24: 343–346
Becker Y (1971) Antitrachoma activity of rifamycin B and 8–0-acetylrifamycin S. Nature 231: 115–116
Becker Y (1978) The Chlamydia: molecular biology of procaryotic obligate parasites of eucaryocytes. Microbiol Rev 42: 274–306
Becker Y, Asher Y (1972) Synthesis of trachoma agent proteins in emetine-treated cells. J Bact 109: 966–970
Becker Y, Zakay-Rones Z (1969) Rifampicin—A new antitrachoma agent. Nature 222: 851–853
Becker Y, Asher Y, Himmel N, Zakay-Rones Z, Maythar B (1969) Rifampicin inhibition of trachoma agent in vivo. Nature 224: 33–34
Becker Y, Asher Y, Himmel N, Zakay-Rones Z (1970) Antitrachoma activity of rifampicin and rifamycin SV derivatives. Nature 225: 454–455
Ben-Ishai A, Heller E, Goldblum N, Becker Y (1969) Rifampicin and poxvirus replication. Nature 224: 29–32
Binda G, Domenichini E, Gottardi A, Orlandi B, Ortelli E, Pacini B, Fowst G (1971) Rifampicin, a general review. Arzneimittel-Forschung 12a: 1907–1976
Bishop JM (1978) Retroviruses. Ann Rev Biochem 47: 35–88
Bissell M, Hatie C, Tischler A, Calvin M (1974) Preferential inhibition of the growth of virus-transformed cells in culture by rifazone-82, a new rifamycin derivative. Proc Natl Acad Sci USA 71: 2520–2524
Borden EC, Brockman WW, Carter WA (1971) Selective inhibition by streptovaricin of splenomegaly induced by Rauscher leukemia virus. Nature New Biol 232: 214–216
Bouch J, Zechel K, Kornberg A (1975) DnaG gene product, a rifampicin resistant RNA polymerase, initiates the conversion of a single-stranded coliphage DNA to its duplex replicative form. J Biol Chem 250:5995–6001
Brufani M (1977) The Ansamycins. In: Sammes PG (ed) Topics in antibiotic chemistry, vol 1. Aminoglycosides and ansamycins. Ellis Horwood, Chichester, pp 93–217
Brufani M, Cerrini S, Fedeli W, Vaciago A (1974) Rifamycins: an insight into biological activity based on structural investigations. J Mol Biol 87: 409–435
Brutlag D, Schekman R, Kornberg A (1971) A possible role for RNA polymerase in the initiation of M13 DNA synthesis. Proc Natl Acad Sci USA 68: 2826–2829
Calvin M, Joss UR, Hackett AJ, Owens RB (1971) Effect of rifampicin and two of its derivatives on cells infected with Moloney sarcoma virus. Proc Natl Acad Sci USA 68: 1441–1443
Carter WA, Brockman WW, Borden EC (1971) Streptovaricins inhibit focus formation by MSV(MLV) complex. Nature New Biol 232: 212–214
Chamberlin M (1976) RNA polymerase-An overview. In: Losick R, Chamberlin M (eds) RNA polymerase. Cold Spring Harbor Laboratory, New York, pp 17–67
Chamberlin M, McGrath J, Waskell L (1970) New RNA polymerase from Escherichia coliinfected with bacteriophage T7. Nature 228: 227–231
Costanzo F, Fiume L, La Placa M, Mannini-Palenzona A, Novello G, Stirpe F (1970) Ribonucleic acid polymerase induced by vaccinia virus: lack of inhibition by rifampicin and a-amanitin. J Virol 5: 226–269
Cricchio R, Cietto G, Rossi E, Arioli V (1975) Farmaco Ed Sci 30: 704
Dales S, Mosbach ED (1968) Vaccinia as a model for membrane biogenesis. Virol 35: 564–583
Darougar S, Viswalingam M, Treharne JD, Kinnison JR, Jones BR (1977) Treatment of TRIC infection of the eye with rifampicin or chloramphenicol. Brit J Opthalm 61: 255–259
Das J, Maniloff J (1976) Replication of mycoplasma virus MVL51. IV Inhibition of viral synthesis by rifampin. J Virol 18: 969–976
DiCioccio RA, Srivastava SBI (1978) Structure-activity relationships and specificity of inhibition of DNA polymerases from normal and leukemia cells of man and from simian sarcoma virus by rifamycin derivatives. J Natl Cancer Instit 61: 1187–1194
Diggelman H, Weissman C (1969) Rifampicin inhibits focus formation in chick fibroblasts infected with Rous sarcoma virus. Nature 224: 1277–1279
Engelberg H (1972) Inhibition of RNA bacteriophage replication by rifampicin. J Mol Biol 68: 541–546
Engelberg H, Soudry E (1971) Inhibition of ribonucleic acid bacteriophage release from its host by rifampin. J Virol 7:847–848
Engelberg H, Soudry E (1971) Ribonucleic acid bacteriophage release: requirement for host-controlled protein synthesis. J Virol 8: 257–264
Engelberg H, Brudo I, Israeli-Reches M (1975) Discriminative effect of rifampin on RNA replication of various RNA bacteriophages. J Virol 16: 340–347
Essani K, Dales S (1979) Biogenesis of vaccinia: evidence for more than 100 polypeptides in the virion. Virol 95: 385–394
Esteban M (1977) Rifampicin and vaccinia DNA. J Virol 21: 796–801
Esteban M, Holowczak JA (1977) Replication of vaccinia DNA in mouse L cells. Virol 78: 57–75
Fallon RJ, Lees AW, Allan GW, Smith J, Tyrrell WF (1975) Probenecid and rifampicin serum levels. Lancet 11: 792–794
Follett EAC, Pennington TH (1971) Antiviral effect of constituent parts of the rifampicin molecule. Nature 230: 117–118
Follett EAC, Pennington TH (1973) The mode of action of rifamycins and related compounds on poxvirus. Advances in Virus Res 18: 105–142
Frolova LY, Meldrays YA, Kochkina LL, Giller SA, Eremeyev AV, Grayevskaya NA, Kisselev LL (1977) DNA polymerase inhibitors. Rifamycin derivatives. Nucleic Acids Res 4: 523–538
Fromageot H, Zinder N (1968) Growth of bacteriophage f2 in E. colitreated with rifampicin. Proc Natl Acad Sci USA 61: 184–191
Furukawa T, Tanaka S, Plotkin SA (1975) Inhibition of human cytomegalovirus by rifampin. J Gen Virol 28: 355–362
Gallo RC (1971) Reverse transcriptase, the DNA polymerase of oncogenic RNA viruses. Nature 234: 194–198
Gallo RC, Yang SS, Ting RC (1970) RNA-dependent DNA polymerase of human acute leukaemic cells. Nature 228: 927–929
Gallo RC, Yang SS, Smith RG, Herrera F, Ting RC, Bobrow SN, Davis C, Fujioka S (1971) RNA- and DNA-dependent DNA polymerases of human normal and leukemic cells. In: Silvestri L (ed) The biology of oncogenic viruses. North-Holland, Amsterdam, pp 210–220
Gallo RC, Smith RC, Whang-Peng J, Ting RC, Yang SS, Abrell JW (1972) RNA tumor viruses, DNA polymerases, and oncogenesis: some selective effects of rifampicin derivatives. Medicine 51: 159–168
Geiduschek EP, Sklar J (1969) Continual requirement for a host RNA polymerase component in bacteriophage development. Nature 221: 833–836
Gerard GF, Gurgo C, Grandgenett DP, Green M (1973) Rifamycin derivatives: specific inhibitors of nucleic acid polymerases. Biochem Biophys Res Commun 53: 194–201
Geshelin P, Berns KI (1974) Characterization and localization of the naturally occurring cross-links in vaccinia virus DNA. J Mol Biol 88: 785–796
Gielkins A, Burghouts J, Bloemendal H (1972) Inhibitory effect of rifampicin on Rauschervirus-induced murine leukemia. Int J Cancer 9: 595–598
Grado C, Ohlbaum A (1973) The effect of rifampicin, actinomycin D, and mitomycin C on poliovirus and foot-and-mouth disease virus replication. J Gen Virol 21: 297–303
Green M, Rokutanda M, Fujinaga K, Ray RK, Rokutanda H, Gurgo C (1970) Mechanism of carcinogenesis by RNA tumor viruses. I. An RNA-dependent DNA polymerase in murine sarcoma cells. Proc Natl Acad Sci USA 67: 385–393
Green M, Rokutanda M, Fujinaga K, Rokutanda H, Gurgo C, Ray RK, Parsons JT (1971) Synthesis of DNA by RNA tumor viruses and viral RNA by virus transformed cells. In: Silvestri L (ed) The biology of oncogenic viruses. North-Holland, Amsterdam, pp 193–205
Green M, Bragdon J, Rankin A (1972) B-cyclic amine derivatives of rifamycin: strong inhibitors of the DNA polymerase activity of RNA tumor viruses. Proc Natl Acad Sci USA 69:1294–1298
Green M, Gerard GF, Grandgenett DP, Gurgo C, Rankin AM, Green MR, Cassel DM (1974a) Biochemical suppression of tumor virus activity. Cancer 34:1427–1438
Green M, Gurgo C, Gerard G, Grandgenett DP, Shimada K (1974b) Inhibition of DNA polymerases of RNA tumor viruses and cells by rifamycin SV derivatives. In: Molecular studies in viral neoplasia. William and Wilkins Co, Baltimore, pp 258–288
Grimley PM, Rosenblum EN, Mims SJ, Moss B (1970) Interruption by rifampicin of an early stage in vaccinia virus morphogenesis: accumulation of membranes which are precursors of virus envelopes. J Virol 6: 519–533
Grimley PM, Moss B (1971) Similar effect of rifampicin derivatives on vaccina virus morphogenesis. J Virol 8: 225–231
Gurgo C (1977) Rifamycins as inhibitors of DNA and RNA polymerases. Pharm Ther Part A 2: 139–169
Gurgo C (1980) Rifamycins as inhibitors of DNA and RNA polymerases. In: Sarin P, Gallo RC (eds) The international encyclopedia of pharmacology and therapeutics, section 103. Pergamon Press, Oxford, pp 159–189
Gurgo C, Grandgenett DP (1977) Different modes of inhibition of purified ribonucleic acid polymerase of avian myeloblastosis virus by rifamycin SV derivatives. Biochemistry 16: 786–792
Gurgo C, Craig E, Schlessinger D, Afolayan A (1971a) Polyribosome metabolism in Escherichia coli starved for an amino acid. J Mol Biol 62:525–535
Gurgo C, Ray RK, Thiry L, Green M (1971 b) Inhibition of the RNA and DNA dependent polymerase activities of RNA tumor viruses. Nature 229:111–114
Gurgo C, Ray RK, Green M (1972) Rifamycin derivatives strongly inhibiting RNA-DNA polymerase (reverse transcriptase) of murine sarcoma viruses. J Natl Cancer Instit 49: 61–79
Gurgo C, Grandgenett DP, Gerard GF, Green M (1974) Interaction of purified ribonucleic acid directed deoxyribonucleic acid polymerase of avian myeloblastosis virus and murine sarcoma-leukemia virus with a rifamycin SV derivative. Biochemistry 13: 708–713
Gurgo C, Grandgenett DP, Gerard GF, Green M (1975) Mechanism of inhibition of RNA tumor virus reverse transcriptase by rifamycin SV derivatives. In: Kolber A (ed) Tumor virus-host cell interaction. Plenum, New York, pp 273–291
Hackett AJ, Sylvester SS (1972a) Cell line derived from BALB/3T3 that is transformed by murine leukemia virus: a focus assay for leukemia virus. Nature New Biol 239:164–166
Hackett AJ, Sylvester SS (1972b) Inhibition of MLV-induced transformation in BALB/3T3 derived cells. Nature New Biol 239: 166–167
Hackett AJ, Owens RB, Calvin M, Joss U (1972) Inhibition of MSV viral function by rifampicin derivatives. Medicine 51: 175–180
Halsted C, Minnefor A, Lietman P (1972) Inhibition of cytomegalovirus by rifampin. J Infectious Dis 125: 552–555
Haselkorn R, Vogel M, Brown R (1969) Conservation of the rifamycin sensitivity of transcription during T4 development. Nature 221: 836–838
Heller E, Argaman M, Levy H, Goldblum N (1969) Selective inhibition of vaccinia virus by the antibiotic rifampicin. Nature 222: 273–274
Hemphill H, Whiteley H, Brown L, Doi R (1969) The effect of rifampin on the production of ß22 phage by Bacillus subtilis. Biochem Biophys Res Commun 37: 559–566
Higashi A, Komano T (1977) Inhibition of bacteriophage CX174 replicative-form DNA replication by rifampicin. Agric Biol Chem 41: 383–388
Higashide E, Asai M, Ootsu K, Tanida S, Kozai Y, Hasegawa T, Kishi T, Sugino Y, Yoneda M (1977) Ansamitocin, a group of novel maytansinoid antibiotics with antitumor properties from Nocardia. Nature 270: 721–722
Hughes AM, Calvin M (1976) Effect of some rifamycin derivatives on chemically induced mammary tumors in rats. Cancer Letters 2: 5–10
Igel HJ, Huebner RJ, Turner HC, Kotin P, Falk HL (1969) Mouse leukemia virus activation by chemical carcinogens. Science 166: 1624–1626
Jockusch H, Ball LA, Kaesbert P (1970) Synthesis of polypeptides directed by the RNA of phage Qß. Virol 42: 401–414
Johnston DE, McClure WR (1976) Abortive initiation of in vitro RNA synthesis on bacteriophage 2DNA. In: Losick R, Chamberlin M (eds) RNA polymerase. Cold Spring Harbor Laboratory, New York, pp 413–428
Joss UR, Hughes AM, Calvin M (1973) Effect of dimethylbenzyldesmethylrifampicin (DMB) on chemically induced mammary tumors in rats. Nature New Biol 242: 88–90
Kates JR, McAuslan BR (1967) Poxvirus DNA-dependent RNA polymerase. Proc Natl Acad Sci USA 58: 134–141
Katz E, Moss B (1970) Formation of a vaccinia virus structural polypeptide from a higher molecular weight precursor: inhibition by rifampicin. Proc Natl Acad Sci USA 66: 677–684
Katz E, Moss B (1970) Vaccinia virus structural polypeptide derived from a high-molec-ular-weight precursor: formation and integration into virus particles. J Virol 6: 717–726
Katz E, Grimley P, Moss B (1970) Reversal of antiviral effects of rifampicin. Nature 227: 1050–1051
Kenwright S, Levi AJ (1973) Impairment of hepatic uptake of rifamycin antibiotics by probenecid and its therapeutic implications. Lancet 11: 1401–1405
Kishi T, Yamana H, Muroi M, Harada S, Asai M, Hasegawa T, Mizuno K (1972) Tolypomycin, a new antibiotic. III. Isolation and characterization of tolypomycin Y. J Antibiotics 25: 11
Kupchan SM, Komoda Y, Court WA, Thomas GT, Smith RM, Karim A, Gilmore CJ, Haltiwanger RC, Bryan RF (1972) Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 94: 1354–1356
Kupchan SM, Sneden AT, Branfman AR, Howie GA, Rebhun LI, Mclvor WE, Wang RW, Schnaitman TC (1978) Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. J Med Chem 21: 31–37
Lancini GC, Sartori G (1968) Rifamycins. LXI. In vivo inhibition of RNA synthesis by rifamycins. Experientia 24: 1105–1106
Lancini GC, Zanichelli W (1977) Structure-activity relationships in rifamycins. In: Perlman D (ed) Structure-activity relationships among the semisynthetic antibiotics. Academic Press, New York, pp 531–600
Lancini GC, Cricchio R, Thiry L (1971) Antiviral activity of rifamycins and N-aminopiperazines. J Antibiotics 24: 64–66
Maitra U (1971) Induction of a new RNA polymerase in Escherichia coliinfected with bacteriophage T3. Biochem Biophys Res Commun 43: 443–450
Margalith P, Pagani H (1961) Rifomycins. XIV. Production of rifomycin B. Appli Microbiol 9: 325–334
Marino P, Baldi I, Tocchini-Valentini G (1968) Effect of rifamycin on DNA dependent RNA polymerase and on RNA phage growth. Cold Spring Harbor Symp Quant Biol 33: 125–127
McAuslan BR (1969) Rifampicin inhibition of vaccinia replication. Biochem Biophys Res Commun 37: 289–295
McCormick DP, Wenzel RP, Smith EP, Beam WE (1972) Failure of rifampicin to inhibit adenovirus replication. Antimicrob Ag Chemother 2: 326–328
Meir D, Hofschneider P (1972) Effect of rifampicin on the growth of bacteriophage M12. FEBS Letters 25: 179–183
Milavetz B, Horoszewicz J, Rinehart K, Carter W (1976) An immobilized template assay of reverse transcriptase inhibition by ansamycins. Proc Am Assoc Cancer Res 17: 179
Mizuno S, Yamazaki H, Nitta K, Umezawa H (1968a) Inhibition of DNA-dependent RNA polymerase reaction of E. coli by streptovaricin. Biochim Biophys Acta 157:322–332
Mizuno S, Yamazaki H, Nitta K, Umezawa H (1968 b) Inhibition of initiation of DNA-de-pendent RNA synthesis. Biochem Biophys Res Commun 30:379–385
Moreau M (1974) Inhibition of a vesicular stomatitis virus mutant by rifampin. J Virol 14: 517–521
Moreau M, Sanzey B (1977) Rifampin-susceptible mutant of vesicular stomatitis virus: protein and RNA synthesis. J Virol 21: 41–53
Moshkowitz A, Goldblum N, Heller E (1971) Studies on the antiviral effect of rifampicin in volunteers. Nature 229: 422–424
Moss B, Rosenblum ED (1973) Protein cleavage and poxvirus morphogenesis: tryptic peptide analysis of core precursors accumulated by blocking assembly with rifampicin. J Mol Biol 81: 267–269
Moss B, Katz E, Rosenblum EN (1969 ) Vaccinia virus directed RNA and protein synthesis in the presence of rifampicin. Biochem Biophys Res Commun 36:858–865
Moss B, Rosenblum ED, Katz E, Grimley PM (1969 b) Rifampicin: a specific inhibitor of vaccinia virus assembly. Nature 224:1280–1284
Moss B, Rosenblum EN, Grimley PM (1971) Assembly of vaccinia virus particles from polypeptides made in the presence of rifampicin. Virol 45: 123–134
Moss B, Rosenblum E, Grimley P, Mims S (1972) Rifamycins: modulation of specific antipoxviral activity by small substitutions on the piperazinyliminomethyl side chain. Antimicrob Ag Chemother 2: 181–185
Munyon W, Paoletti E, Grace JT (1967) RNA polymerase in purified infectious vaccinia. Proc Natl Acad Sci USA 58: 2280–2287
Nagayama A, Pogo BGT, Dales S (1970) Biogenesis of vaccinia: separation of early stages from maturation by means of rifampicin. Virol 40: 1039–1051
Naimski P, Chroboczek J (1977) Effect of rifampicin on the infectivity of RNA bacteriophage f2. Eur J Biochem 76: 419–423
Nevins JR, Joklik WK (1977) Isolation of and properties of the vaccinia virus DNA-dependent RNA polymerase. J Biol Chem 252: 6930–6938
O’Connor T, Schiop-Stansly P, Sethi VS, Hadidi A, Okano P (1974) Antiviral antibiotics: inhibition of focus-formation in human or mouse cell cultures by sarcoma-inducing oncornaviruses with rifamycins. Intervirol 3: 63–83
O’Connor TE, Aldrich C, Hadidi A, Lomax N, Okano P, Sethi S, Wood HB (1975) Maytansine and geldanamycin inhibition of transformation of mouse cell cultures infected with murine sarcoma virus. Proc Am Assoc Cancer Res 16: 29
Ootsu K, Kozai Y, Takeuchi M, Ikeyama S, Igarashi K, Tsukamoto K, Sugino Y, Tashiro T, Tsukagoshi S, Sakurai Y (1980) Effects of new antimitotic antibiotics, ansamitocins, on the growth of murine tumors in vivo and on the assembly of microtubules in vitro. Cancer Res 40: 1707–1717
Oppolzer W, Prelog V, Sensi P (1964) Konstitution des Rifamycins B und verwandter Rifamycine. Experientia 20: 336–339
Passent J, Kaesberg P (1971) Effect of rifampin on the development of ribonucleic acid bacteriophage Qß. JVirol 8: 286–292
Pennington TH, Follett EAC (1971) Inhibition of poxvirus maturation by rifamycin derivatives and related compounds. J Virol 7: 821–829
Pennington TH, Follett EAC, Szilagyi JF (1970) Events in vaccinia virus-infected cells following the reversal of the antiviral action of rifampicin. J Gen Virol 9: 225–237
Pennington TH (1973) Vaccinia virus morphogenesis: a comparison of virus-induced antigens and polypeptides. J Gen Virol 19: 65–79
Pogo BGT (1971) Biogenesis of vaccina: effect of rifampicin on transcription. Virol 44: 576–581
Quintrell NA, McAuslan BR (1970) Inhibition of poxvirus replication by streptovaricin. J Virol 6: 485–491
Rana M, Pinkerton H, Rankin A (1975) Effect of rifamycin and tilorone derivatives on Friend virus leukemia in mice. Proc Soc Exp Biol Med 150: 32–35
Remillard S, Rebhun L, Howie GA, Kupchan SM (1975) Antimitotic activity of the potent inhibitor maytansine. Science 189: 1002–1005
Rinehart KL (1972) Antibiotics with ansa rings. Accounts of Chemical Research 5: 57–64
Riva S, Silvestri L (1972) Rifamycins: a general view. Ann Rev Microbiol 26: 199–224
Riva S, Fietta A, Silvestri LG (1972) Mechanism of action of a rifamycin derivative (AF013) which is active on the nucleic acid polymerases insensitive to rifampicin. Biochem Biophys Res Commun 49: 1263–1271
Robinson H, Robinson W (1971) Inhibition of growth of uninfected and Rous sarcoma virus-infected chick embryo fibroblasts by rifampicin. J Natl Ca Instit 46: 785–788
Rokutanda M, Rokutanda H, Green M, Fujinaga K, Ray RK, Gurgo C (1970) Formation of viral RNA-DNA hybrid molecules by the DNA polymerase of sarcoma-leukemia viruses. Nature 227: 1026–1028
Rothwell J, Yamazaki H (1972) Limited production of R17 ribonucleic acid phage in the presence of rifampicin. Biochemistry 11: 3333–3338
Schekman R, Wickner W, Westergaard O, Brutlag D, Geider K, Bertsch L, Kornberg A (1972) Initiation of DNA synthesis: synthesis of OX174 replicative form requires RNA synthesis resistant to rifampicin. Proc Natl Acad Sci USA 69: 2691–2695
Schlessinger D, Gurgo C, Luzzato L, Apirion D (1969) Polyribosome metabolism in growing and nongrowing E. coli. Cold Spring Harbor Symp Quant Biol 34: 231–242
Sensi P (1975) Recent progress in the chemistry and biochemistry of rifamycins. Pure and Applied Chem 41: 15–29
Sensi P, Margalith P, Timbal M (1959) Rifomycin, a new antibiotic-preliminary report. Farmaco, Ed Sci 14: 146–147
Sensi P, Greco A, Ballotta R (1959b) Rifomycins. I. Isolation and properties of rifomycin B and rifomycin complex. Antibiotics Ann, pp 262–270
Sethi VS, Okano P (1976) Interaction of rifamycins with mammalian nucleic acid polymerizing enzymes. Biochim Biophys Acta 454: 230–247
Shannon W, Westbrook L, Schabel F (1974) Inhibition of Gross murine leukemia virus replication by rifamycin SV and certain of its derivatives in vitro. Intervirol 3: 84–96
Silverstein S, Billen D (1971) Transcription: role in the initiation and replication of DNA synthesis in Escherichia coliand 4X174. Biochim Biophys Acta 247: 383–390
Sinkovics J (1971) Antitumor activity of L-asparaginase and rifampicin. Lancet II:48–49
Smith HS, Hackett AJ (1974) The specificity of dimethylbenzylrifampicin as an inhibitor of viral induced transformation. Proc Natl Acad Sci USA 71: 2770–2772
Smith R, Whang-Peng J, Gallo RC, Levine P, Ting RC (1972) Selective toxicity of rifamycin derivatives for leukaemic human leucocytes. Nature New Biol 236: 166–171
Spiegelman S, Burney A, Das MR, Keydar J, Schlom J, Travnicek M, Watson K (1970) Characterization of the products of RNA-directed DNA polymerases in oncogenic RNA viruses. Nature 227: 563–567
Subak-Sharpe JH, Timbury MC, Williams JF (1969) Rifampicin inhibits the growth of some mammalian viruses. Nature 222: 341–345
Szabo C, Bissell MJ (1978) Antiviral action of a rifamycin derivative: formation of Rous sarcoma virus particles deficient in 60 to 70S RNA. J Virol 25: 944–947
Szabo C, Bissell MJ, Calvin M (1976) Inhibition of infectious Rous sarcoma virus production by a rifamycin derivative. J Virol 18: 445–453
Szilâgyi JF, Pennington TH (1971) Effect of rifamycins and related antibiotics on the deoxyribonucleic acid-dependent ribonucleic acid polymerase of vaccinia virus particles. J Virol 8: 133–141
Takeda Y, Oyama Y, Nakajima K, Yura T (1969) Role of host RNA polymerase for lambda phage development. Biochem Biophys Res Commun 36: 533–538
Tan KB, McAuslan BR (1970) Effect of rifampicin on poxvirus protein synthesis. J Virol 6: 326–332
Temin H (1971) The protovirus hypothesis: speculations on the significance of RNA-directed DNA synthesis for normal development and for carcinogenesis. J Natl Cancer Instit 46:III-VII
Temin H, Mizutani S (1970) RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 226: 1211–1213
Thiry L, Lancini G (1970) Inhibition of vaccinia virus growth by 1-methyl-4-aminopiperazine. Nature 227: 1048–1050
Thiry L, Lancini G (1972) Mode of action of rifamycin and aminopiperazine derivatives on animal viruses and cells. FEBS Symp 22: 177–192
Thompson FM, Tischler AN, Adams J, Calvin M (1974) Inhibition of three nucleotide polymerases by rifamycin derivatives. Proc Natl Acad Sci USA 71: 107–109
Ting RC, Yang SS, Gallo RC (1972) Reverse transcriptase, RNA tumor virus transformation and derivatives of rifamycin SV. Nature New Biol 236: 163–166
Tischler AN, Joss UR, Thompson FM, Calvin M (1973) Synthesis of some rifamycin derivatives as inhibitors of RNA-instructed DNA polymerase function. J Med Chem 16: 1071–1075
Tischler AN, Thompson FM, Libertini LJ, Calvin M (1974) Rifamycin derivatives as inhibitors of a ribonucleic acid instructed deoxyribonucleic acid polymerase function. Effect of lipophilicity. J Med Chem 17: 948–952
Toolan H, Ledinko N (1972) Effect of rifampicin on the development of tumors induced by adenovirus in male hamsters. Nature New Biol 237: 200–202
Ueda Y, Dumbell KR, Tsuruhara T, Tagaya I (1978) Studies on Cotia virus—an unclassified poxvirus. J Gen Virol 40: 263–276
Vaheri A, Hanafusa H (1971) Effect of rifampicin and a derivative on cells transformed by Rous sarcoma virus. Cancer Res 31: 2032–2036
Wehrli W (1977) Ansamycins: chemistry, biosynthesis, and biological activity. Topics in Current Chemistry 72: 22–49
Wehrli W, Staehelin M (1971) Actions of the rifamycins. Bact Rev 35: 290–309
Wehrli W, Handschin J, Wunderli W (1976) Interaction between rifampicin and DNA dependent RNA polymerase of E. coli.In: Losick R, Chamberlin M (eds) RNA polymerase. Cold Spring Harbor Laboratory, New York, pp 397–412
Wickner W, Brutlag D, Schekman R, Kornberg A (1972) RNA synthesis initiates in vitro conversion of M13 DNA to its replicative form. Proc Natl Acad Sci 69: 965–969
Wigand R, Vujic A, Schöner M (1974) Inhibition of adenovirus multiplication by rifamycin derivatives. Acta Virol 18: 113–120
Wu AM, Gallo RC (1974) Interaction between murine type-C virus RNA-directed DNA polymerases and rifamycin derivatives. Biochim Biophys Acta 340: 419–436
Wu AM, Ting RCY, Gallo RC (1973) RNA-directed DNA polymerase and virus-induced leukemia in mice. Proc Natl Acad Sci USA 70: 1298–1302
Wu RS, Wolpert-DeFilippes MK, Quinn FR (1980) Quantitative structure-activity correlations of rifamycins as inhibitors of viral RNA-directed DNA polymerase and mammalian a and ß DNA polymerases. J Med Chem 23: 256–261
Yang SS, Herrera F, Smith R, Reitz M, Lancini G, Ting R, Gallo RC (1972) Rifamycin antibiotics: inhibitors of Rauscher murine leukemia virus reverse transcriptase and of purified DNA polymerases from human normal and leukemic lymphoblasts. J Natl Cancer Instit 49: 7–25
Zakay-Rones Z, Becker Y (1970) Anti-poxvirus activity of rifampicin associated with hydrazone side chain. Nature 226: 1162–1163
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gurgo, C., Bridges, S., Green, M. (1982). Rifamycins. In: Came, P.E., Caliguiri, L.A. (eds) Chemotherapy of Viral Infections. Handbook of Experimental Pharmacology, vol 61. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-68487-6_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-68487-6_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-68489-0
Online ISBN: 978-3-642-68487-6
eBook Packages: Springer Book Archive